08/04 Taiwan BIO Weekly
2025-08-04 |
| Taiwan BIO Weekly |
| New Force in Vaccine National Team: NHRI Spin-off 'TaiU' Completes US$2M Seed Round Led by MVL Seed Fund Press release 1 August, 2025 Taiwan Universe BioMedicine (TaiU), a startup spun off from the National Health Research Institutes (NHRI), today announced the completion of a NT$60 million (approx. US$2 million) seed funding round with assistance from Mosaic Venture Lab (MVL). The round, led by Mosaic Seed Fund, also secured a matching investment from the National Development Fund, supported by the SMESA, MOEA, and the NiEA. More... |
| Foresee Pharmaceuticals' files new prostate cancer drug approval in Singapore 31 July, 2025 Foresee Pharmaceuticals (TW: 6576) announced that its licensing partner Changchun GeneScience Pharmaceutical has submitted a new drug application for the prostate cancer new formulation CAMCEVI 42mg to Singapore's Health Sciences Authority (HSA). More... (in Chinese) |
| HCmed Innovations' respiratory-triggered nebulizer receives US FDA approval 31 July, 2025 HCmed Innovations (TW: 6934), specializing in inhalation drug-device combination CDMO products, recently announced that its respiratory-triggered nebulizer, AdheResp, has officially received FDA 510(k) clearance in the United States. It is the world's first US FDA-certified respiratory-triggered nebulizer with built-in connectivity features on the market. Additionally, AdheResp is currently the only advanced nebulizer device with mass production capability, able to support pharmaceutical clients' clinical trial needs. More... (in Chinese) |
| BIONET Therapeutics' umbilical cord mesenchymal stem cell exosomes receive FDA drug approval 31 July May, 2025 BIONET Therapeutics (TW: 7808) announced it had received US FDA approval of its Drug Master File (DMF) Type II registration application for its independently developed umbilical cord mesenchymal stem cell exosome drug substance (UCMSC Exosomes). The company stated that this DMF approval not only benefits the company's new drug development but also provides a valuable technical dossier for partners intending to use BIONET UCMSC Exosomes as a drug substance. The approval is expected to facilitate the product's international business expansion and provide stable raw material support for global partners advancing safer and more effective exosome (extracellular vesicle) therapies. More... (in Chinese) |
| Steminent Biotherapeutics signs tripartite MOU with Kohjin Bio and Purple Win to develop customized cell culture media 30 July, 2025 New drug company Steminent Biotherapeutics (TW: 7729) announced on the 29th that it had signed a tripartite Memorandum of Understanding (MOU) with Kohjin Bio and Purple Win to jointly develop a customized cell culture media project. Steminent Biotherapeutics stated that this collaboration will establish an exclusive supply chain, helping to enhance raw material stability and reduce manufacturing costs. This will further support the company's commercialization plans and long-term competitiveness in cell therapy and regenerative medicine product development. More... (in Chinese) |
| ACRO Biomedical signs licensing agreement with Vietnam's CT Group 30 July, 2025 ACRO Biomedical (TW: 6748) announced that it has signed an international licensing agreement with Vietnam's state-level enterprise CT Group. Under the 10-year agreement, CT Group will serve as the exclusive distributor across all 10 ASEAN countries and pay milestone-based royalties totaling US$10 million based on shipment volume. After product approval, CT Group has also committed to minimum annual orders of at least US$10 million. The deal is expected to significantly boost ACRO Biomedical's revenue and profit. More... (in Chinese) |
| Gongwin Biopharm's canine lung cancer drug expected to launch in Taiwan in Q3 30 July, 2025 Gongwin Biopharm-KY (TW: 6617) recently held an investor meeting where it stated that in the second half of the year the company will continue to expand the market share of its human lung cancer drug PTS302 in mainland China and accelerate global regulatory approvals, while also aiming to obtain drug approval treating malignant canine melanoma in Taiwan with a launch in Q3. This would make PTS302 a drug crossing both human and animal oncology markets. More... (in Chinese) |
| Orient Pharma to list on TPEx by end of August 29 July, 2025 Orient Pharma (TW: 4166), a subsidiary of Orient EuroPharma (TW: 4120), is expected to go public on the Taipei Exchange (TPEx) by the end of August. With three major technology platforms creating differentiated competitive advantages, Orient Pharma focuses on core therapeutic areas such as cardiovascular and central nervous system disorders. The company currently has three products on the market and plans to launch four additional new drugs by 2028. More... (in Chinese) |
| MountainVet Biotech launches Taiwan's first pet stem cell storage service, targeting aging pet market 29 July, 2025 To tap into the growing aging pets market, MountainVet Biotech announced the launch of Taiwan's first autologous stem cell and exosome storage service for pets, marking a significant step into the era of regenerative medicine in Taiwan's veterinary field. According to the company, it has partnered with over 250 animal hospitals across Taiwan and has accumulated experience in processing cells from more than 3,000 pets. According to data from the Council of Agriculture, by the end of 2023, the number of registered dogs and cats in Taiwan had surpassed 2.5 million, with a rapidly rising proportion of senior pets aged 7 and above. Experts point out that as Taiwan's pet population ages, regenerative medicine is emerging as a key trend in veterinary care. More... (in Chinese) |
| K.N.A. Inter Pharma Partners with [Taiwan's] Diamond Biotechnology to Elevate Thailand’s Beauty Industry into a Global Medical Device Manufacturing Hub Press release 29 July, 2025 K.N.A. Inter Pharma Co., Ltd. has joined forces with a team of leading aesthetic clinic executives and medical professionals to announce a groundbreaking partnership with Diamond Biotechnology Co., Ltd., one of the global biotechnology leaders specialized in innovative biomedical products focusing on aesthetic and medical applications with headquarters in Taiwan. More... |
| What makes a smart hospital? It's not technology 29 July, 2025 Adopting and implementing every technology in the market is not what makes a smart hospital. In his keynote presentation at HIMSS25 APAC, Dr Kun-ju Lin, deputy information security chief at Chang Gung Memorial Hospital, Linkou (CGMH) in Taiwan, shared their journey in building a connected, smart health ecosystem. CGMH, he said, has been working to digitalise its systems for the past 20 years. In 2015, when they were assessed for their baseline EMR system maturity, they realised they were not close to becoming a smart hospital. More... |
| DoIT MOEA AI-Enhanced Vaccines and Anti-Pulmonary Inflammatory Drugs Shine at BIO Asia-Taiwan 2025: Health Maintenance, Prevention, and Treatment-A Triple Strategy for a Resilient and Healthy Taiwan 28 July, 2025 The Department of Industrial Technology (DoIT) of the Ministry of Economic Affairs (MOEA) convened three research foundations-ITRI (Industrial Technology Research Institute), FIRDI (Food Industry Research and Development Institute), and the Development Center for Biotechnology (DCB)-to establish the DoIT pavilion, which held its opening ceremony at BIO Asia-Taiwan 2025. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |